UA103544C2 - Кристалічна форма і цинкової солі розувастатину - Google Patents

Кристалічна форма і цинкової солі розувастатину

Info

Publication number
UA103544C2
UA103544C2 UAA201201836A UAA201201836A UA103544C2 UA 103544 C2 UA103544 C2 UA 103544C2 UA A201201836 A UAA201201836 A UA A201201836A UA A201201836 A UAA201201836 A UA A201201836A UA 103544 C2 UA103544 C2 UA 103544C2
Authority
UA
Ukraine
Prior art keywords
crystalline form
zinc salt
rosuvastatin zinc
rosuvastatin
salt
Prior art date
Application number
UAA201201836A
Other languages
English (en)
Russian (ru)
Inventor
Ференц Барта
Лакс Дьйорді Кованьїне
Балаж Волк
Йожеф Баркоці
Дьордь Моров'ян
Дьйордь Краснаі
Калман Надь
Дьюла Сіміг
Дьйордь Ружіч
Дьйордь Цлементіш
Імре Капуі
Петер Шлегель
Адріен Кестелі
Жужанна Сент-Кіраллі
Фекете Валерія Хофманне
Янош Імре
Original Assignee
Егіш Дьйодьсердьяр Нільваношан Мюкеде Ресвеньтаршашаг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Егіш Дьйодьсердьяр Нільваношан Мюкеде Ресвеньтаршашаг filed Critical Егіш Дьйодьсердьяр Нільваношан Мюкеде Ресвеньтаршашаг
Publication of UA103544C2 publication Critical patent/UA103544C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Даний винахід стосується кристалічної форми І солі розувастатину цинку (2:1), способу її одержання та її застосування як фармацевтично активного інгредієнта для лікування захворювань, пов'язаних з метаболізмом ліпідів, що включають гіперліпопротеїнемію, гіперхолестеринемію, дисліпідемію і атеросклероз.
UAA201201836A 2009-07-24 2009-07-24 Кристалічна форма і цинкової солі розувастатину UA103544C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/HU2009/000064 WO2011010174A1 (en) 2009-07-24 2009-07-24 Crystalline form i rosuvastatin zinc salt

Publications (1)

Publication Number Publication Date
UA103544C2 true UA103544C2 (uk) 2013-10-25

Family

ID=41258771

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201201836A UA103544C2 (uk) 2009-07-24 2009-07-24 Кристалічна форма і цинкової солі розувастатину

Country Status (11)

Country Link
US (1) US9023838B2 (uk)
EP (1) EP2483248B1 (uk)
JP (1) JP5702778B2 (uk)
CN (1) CN102548971B (uk)
AU (1) AU2009350099B2 (uk)
EA (1) EA020944B1 (uk)
ES (1) ES2598162T3 (uk)
HU (1) HUE029858T2 (uk)
IL (1) IL217898A0 (uk)
UA (1) UA103544C2 (uk)
WO (1) WO2011010174A1 (uk)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230737B1 (hu) * 2010-11-16 2018-01-29 EGIS Gyógyszergyár Nyrt Eljárás rosuvastatin só előállítására
HU231036B1 (hu) * 2013-09-30 2019-12-30 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Koleszterin bioszintézis gátló hatóanyagot és koleszterin abszorpciót gátló hatóanyagot tartalmazó kombinációs gyógyszerkészítmény

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552389A (en) * 2004-08-06 2009-05-31 Transform Pharmaceuticals Inc Statin pharmaceutical compositions and related methods of treatment
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
EP2066644A2 (en) * 2006-08-04 2009-06-10 Glenmark Pharmaceuticals Limited Salts of rosuvastatin and processes for their preparation
HU230637B1 (hu) * 2007-10-12 2017-05-29 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás rosuvastatin intermedierek előállítására
HU230981B1 (hu) * 2007-10-12 2019-08-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás rosuvastatin só előállítására
AU2010205464A1 (en) * 2009-01-15 2011-08-18 Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag Process for the preparation of rosuvastatin salts

Also Published As

Publication number Publication date
EA201290051A1 (ru) 2012-09-28
WO2011010174A8 (en) 2012-07-05
JP5702778B2 (ja) 2015-04-15
EP2483248A1 (en) 2012-08-08
HUE029858T2 (en) 2017-04-28
EP2483248B1 (en) 2016-07-20
EA020944B1 (ru) 2015-02-27
JP2013500250A (ja) 2013-01-07
CN102548971A (zh) 2012-07-04
WO2011010174A1 (en) 2011-01-27
US9023838B2 (en) 2015-05-05
CN102548971B (zh) 2015-09-16
ES2598162T3 (es) 2017-01-25
AU2009350099B2 (en) 2015-10-29
US20120178729A1 (en) 2012-07-12
IL217898A0 (en) 2012-03-29
AU2009350099A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
MY177742A (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
EA202091303A2 (ru) Композиция ингибитора jak для местного применения
WO2010132999A8 (en) Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
MX2012015292A (es) Pirazolo[1, 5]pirimidinas en la forma de agentes antivirales.
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
MX2015011955A (es) Lipidos y composiciones de lipidos para el suministro de agentes activos.
GEP201706620B (en) NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
MX2010010505A (es) Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf).
MY164864A (en) Indenone derivative and pharmaceutical composition comprising same
MY155938A (en) Oral pharmaceutical composition
MX2021010046A (es) Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.
MX2012013478A (es) Composicion para evitar perdida del cabello o estimular crecimiento del cabello.
MX343165B (es) Agonistas del receptor 5-ht4 para el tratamiento de demencia.
MX2013005961A (es) Metodo para la preparacion de compuestos intermediarios farmaceuticos de alta pureza.
IN2013DN02555A (uk)
UA103544C2 (uk) Кристалічна форма і цинкової солі розувастатину
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
MX353991B (es) Agonista del receptor de 5-ht4 como agente procinetico.
MX2013005960A (es) Metodo para preparar sales de rosuvastatina.
HU1000616D0 (en) Crystalline pharmaceutically active ingredient
MX2010011006A (es) Nueva sal de un derivado de pirimidina.
NZ609804A (en) Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
WO2012072791A3 (en) 2-(1-phenyl-4,5,6,7-tetrahydro-1h-indazol-4-yl)ethylamine derivatives useful as sigma receptor inhibitors
WO2010128346A3 (en) Rosuvastatin manganse, copper, iron and zinc salts with high photochemical stability
EP2407454A4 (en) PROPHYLACTIC OR THERAPEUTIC AGENT FOR OPTICAL NERVE DISORDERS COMPRISING A DERIVATIVE OR SALT OF 4,6-DICHLORO-1H-INDOLE-2-CARBOXYLIC ACID AS ACTIVE INGREDIENT